Department of Internal Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
J Neurointerv Surg. 2010 Sep;2(3):221-8. doi: 10.1136/jnis.2010.002675.
To evaluate the efficacy of vertebral augmentation (VA) in cancer patients.
From a retrospectively compiled database, 147 cancer cases (236 levels) were treated with VA. Mean age was 71±12 years and 56.5% were female. Variables evaluated include age, sex, procedure type, vertebral level treated, number of levels treated per procedure and technical approach. Outcomes were assessed by a previously described method retrospectively applied from medical records: a binary system of 'responders' versus 'non-responders' and further subcategorization with a four level pain scale. Two patient groups were analyzed: (1) 147 cancer patients with either osteoporotic or malignant vertebral compression fractures (all compression fractures (ACFs)) and (2) 102 cases with documented metastatic compression fractures (MCFs). Univariate and multivariate analyses determined outcomes.
93% of MCFs and 88.5% of ACFs showed response to treatment (pain improvement or resolution): 30% of ACFs and 31% of MCFs experienced pain resolution. MCFs showed increasing age to be a predictor of response to treatment in univariate (OR=1.79, p=0.04) and multivariate (OR=2.05, p=0.03) analysis. In ACFs, bipedicular needle approach decreased the odds of pain resolution (OR=0.28, p=0.01). In MCFs, lung cancer (OR=0.06, p=0.03) and multiple myeloma (OR=0.10, p=0.01) decreased the odds of pain resolution.
VA provides pain relief for a majority of ACFs and MCFs. Increasing age may be predictive of pain relief outcomes in MCFs. There are special planning, imaging and technical considerations (eg, needle placement) in using VA to treat cancer patients.
评估椎体强化术(VA)在癌症患者中的疗效。
从回顾性编制的数据库中,147 例癌症病例(236 个椎体)接受了 VA 治疗。平均年龄为 71±12 岁,56.5%为女性。评估的变量包括年龄、性别、手术类型、治疗的椎体水平、每次手术治疗的椎体数量和技术方法。通过以前描述的方法从病历中回顾性评估结果:采用“应答者”与“非应答者”的二进制系统,并进一步采用四级疼痛量表进行细分。分析了两组患者:(1)147 例骨质疏松或恶性椎体压缩性骨折(均为压缩性骨折(ACFs))的癌症患者;(2)102 例有记录的转移性压缩性骨折(MCFs)的患者。单变量和多变量分析确定了结果。
93%的 MCFs 和 88.5%的 ACFs 对治疗有反应(疼痛改善或缓解):30%的 ACFs 和 31%的 MCFs 经历了疼痛缓解。MCFs 中,年龄是单变量(OR=1.79,p=0.04)和多变量(OR=2.05,p=0.03)分析中治疗反应的预测因素。在 ACFs 中,双针入路降低了疼痛缓解的可能性(OR=0.28,p=0.01)。在 MCFs 中,肺癌(OR=0.06,p=0.03)和多发性骨髓瘤(OR=0.10,p=0.01)降低了疼痛缓解的可能性。
VA 为大多数 ACFs 和 MCFs 提供了疼痛缓解。在 MCFs 中,年龄的增加可能是疼痛缓解结果的预测因素。在使用 VA 治疗癌症患者时,需要进行特殊的规划、影像学和技术考虑(例如,针的放置)。